November 8, 2018 - Page 32 of 44

NYSE Companies - November 8, 2018

Company to Webcast Presentation Live at 8:00 a.m. ET on Tuesday, November 13th SWINDON, United Kingdom, Nov. 08, 2018 (GLOBE […]

NASDAQ Companies - November 8, 2018

Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) — […]

NASDAQ Companies - November 8, 2018

Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO, Nov. 08, […]

NASDAQ Companies - November 8, 2018

AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA) AZEDRA U.S. Launch Progressing and AZEDRA Added to the […]

NASDAQ Companies - November 8, 2018

SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral […]

NASDAQ Companies - November 8, 2018

CINCINNATI, Nov. 08, 2018 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter […]

NASDAQ Companies - November 8, 2018

OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 […]

NASDAQ Companies - November 8, 2018

Commercial team preparing for potential gene therapy launches BOSTON and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) — Orchard Therapeutics, a […]

NASDAQ Companies - November 8, 2018

Company to Present Latest Findings at 2018 Society for Immunotherapy of Cancer’s (SITC) Annual Meeting NEW YORK, Nov. 08, 2018 […]

NASDAQ Companies - November 8, 2018

PARSIPPANY, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) — Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that members of its management […]